Summary of Ultragenyx Pharmaceutical FY Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Focus**: Development of treatments for rare diseases, with a strategy centered on potent biology and innovative drug development methods [1][2] Core Points and Arguments Product Development and Pipeline - **Commercial Products**: Since going public in 2014, Ultragenyx has four commercial products approved, generating revenue in over 30 countries [2] - **Setrusumab Program**: Recent trials for Setrusumab were disappointing, missing primary endpoints but showing improvements in bone mineral density and patient-reported outcomes [3][4][10] - **Trial Designs**: Two phase 3 studies (Orbit and COSMIC) were conducted, with Orbit being placebo-controlled and COSMIC being active-controlled for younger patients [5][6] - **Fracture Rates**: In the Orbit study, the fracture rates did not show significant differentiation between treatment and placebo groups, raising questions about the drug's efficacy [11][12] - **Bone Mineral Density**: Setrusumab demonstrated substantial improvements in bone mineral density, particularly in trabecular bone, but the expected reduction in fractures was not achieved [10][14] Future Developments - **Gene Therapy Programs**: - **Sanfilippo Syndrome**: A gene therapy program is expected to file for approval soon, with strong data supporting its efficacy [17] - **DTX401 for Glycogen Storage Disease**: A BLA filing was completed, showing significant demand and positive outcomes in reducing cornstarch needs for patients [18][19] - **GTX-102 for Angelman Syndrome**: Phase 3 data is anticipated in the second half of the year, with promising results in developmental improvements [20][21] Financial Outlook - **Revenue Growth**: Expected revenue of $62-$674 million, reflecting a 20% growth rate, with plans for expense and headcount reductions to maintain profitability goals by 2027 [24][25][26] - **Cash Position**: The company has $735 million in cash and anticipates receiving two PRVs before the sunset clause in September [26] Important but Overlooked Content - **Patient-Centric Focus**: Pain management and functional improvements are prioritized by patients, even if regulatory endpoints focus on fracture rates [30][31] - **Regulatory Navigation**: The company is working to understand the data better before approaching regulatory bodies, particularly regarding the discrepancies in fracture rates and patient activity levels [32][34] - **Long-Term Data**: There is an expectation for long-term follow-up data to provide further insights into the efficacy of treatments, particularly for Setrusumab [36] Conclusion Ultragenyx is navigating challenges in its product pipeline while maintaining a strong focus on patient outcomes and revenue growth. The company is poised for significant developments in gene therapy and aims to achieve profitability by 2027, despite setbacks in recent clinical trials.

Financial Performance - Ultragenyx Pharmaceutical Inc. announced preliminary unaudited total revenue for fiscal year 2025, with specific revenue figures for Crysvita® and Dojolvi® to be disclosed in February 2026[6] - Full year results for fiscal year 2025 will be officially reported in February 2026, providing further insights into financial performance[6] Liquidity Position - The company reported cash and investments at the end of fiscal year 2025, indicating a strong liquidity position[6]

Core Insights - Ultragenyx Pharmaceutical Inc. reported preliminary total revenue for 2025 of $672 million to $674 million, exceeding the top end of guidance and representing approximately 20% growth compared to 2024 [1][3] - The company anticipates significant catalysts in 2026, including two potential gene therapy approvals and pivotal Phase 3 data for GTX-102 in Angelman syndrome [1][2] Financial Update - Preliminary revenue for 2025 is estimated at $672 million to $674 million, with Crysvita revenue projected at $480 million to $482 million, reflecting approximately 17% growth from 2024 [3] - Dojolvi revenue for 2025 is estimated at $95 million to $97 million, indicating approximately 9% growth compared to 2024 [3] - As of December 31, 2025, the company reported cash and investments of approximately $735 million [4] Clinical and Regulatory Catalysts - The company plans to present data from the Phase 3 Orbit and Cosmic studies of UX143 (setrusumab) at the J.P. Morgan Healthcare Conference on January 12, 2026 [7] - The rolling submission for DTX401 (pariglasgene brecaparvovec) for glycogen storage disease type Ia was completed in December 2025, with a PDUFA date anticipated in Q3 2026 [7] - UX111 (rebisufligene etisparvovec) for Sanfilippo syndrome type A is on track for BLA resubmission in early 2026 [7] - GTX-102 (apazunersen) data from the Phase 3 Aspire study is expected in the second half of 2026 [7] - Enrollment for UX701 (rivunatpagene miziparvovec) in the pivotal Cyprus2+ study is complete, with data expected in the first half of 2026 [7] Company Overview - Ultragenyx is focused on developing and commercializing therapies for serious rare and ultra-rare genetic diseases, with a diverse portfolio aimed at addressing high unmet medical needs [9] - The management team has extensive experience in the development and commercialization of rare disease therapeutics, emphasizing efficient drug development [10]

Core Insights - Ultragenyx Pharmaceutical Inc. is focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases [3] - The company's CEO, Emil D. Kakkis, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [1] - A live and archived webcast of the presentation will be available on the company's website for 30 days [2] Company Overview - Ultragenyx is committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases [3] - The company has a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need [3] - Ultragenyx's management team has extensive experience in the development and commercialization of rare disease therapeutics [4] - The company's strategy focuses on time- and cost-efficient drug development to deliver safe and effective therapies urgently [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Ultragenyx Pharmaceutical Inc. and its officers or directors, following disappointing Phase 3 study results for setrusumab, which led to a significant drop in the company's stock price [1][3][4]. Group 1: Company Performance - Ultragenyx announced results from two Phase 3 studies for setrusumab, a treatment for bone metabolism conditions, on December 29, 2025 [3]. - Neither study achieved statistical significance for the primary endpoints related to the reduction in annualized clinical fracture rate compared to placebo or bisphosphonates [3]. - Both studies met their secondary endpoints, showing significant improvements in bone mineral density against comparators [3]. Group 2: Stock Market Reaction - Following the announcement of the study results, Ultragenyx's stock price fell by $2.02 per share, representing a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud by Ultragenyx and its management [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Insights - Ultragenyx Pharmaceutical's shares increased by 15.5% following the completion of the rolling submission of a biologics license application (BLA) to the FDA for its AAV gene therapy, DTX401, aimed at treating glycogen storage disease type Ia (GSDIa) [1][7] Company Overview - GSDIa is a rare, life-threatening metabolic disorder affecting approximately 6,000 individuals in commercially accessible regions, with no approved pharmacologic treatments available [2] - If approved, DTX401 will be the first therapy targeting the underlying cause of GSDIa [2] Clinical Data - The BLA submission is supported by robust clinical data, including results from the phase III GlucoGene study, which demonstrated significant reductions in daily cornstarch intake and improved blood glucose control while maintaining low hypoglycemia rates [3][9] - After 96 weeks of treatment with DTX401, patients showed greater reductions in daily cornstarch intake and enhanced euglycemia [8] Market Performance - Over the past six months, Ultragenyx's shares have declined by 37.2%, contrasting with a 25.2% rise in the industry [4] Development Timeline - The rolling submission of the BLA for DTX401 began in August 2025, with the completion of the chemistry, manufacturing, and controls module marking a significant milestone [5][9]

Company Overview - Ultragenyx shares increased by 15.5% to $22.78, following a significant trading volume, despite a prior 40.9% loss over the last four weeks [1] - The stock's rally is attributed to optimism regarding the completion of the rolling submission of a biologics license application (BLA) to the FDA for its AAV gene therapy, DTX401, aimed at treating glycogen storage disease type Ia (GSDIa) [2] Financial Performance - The company is projected to report a quarterly loss of $1.32 per share, reflecting a year-over-year increase of 5%, with expected revenues of $186.9 million, marking a 13.4% rise from the previous year [3] - The consensus EPS estimate for Ultragenyx has remained stable over the past 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Ultragenyx is categorized within the Zacks Medical - Biomedical and Genetics industry, where another company, Insmed, experienced a 1.3% decline to $174.09 and has seen a -16.6% return over the past month [5] - Insmed's consensus EPS estimate has increased by 4.4% over the past month to -$1.33, which is a 0.8% decrease from the previous year's report [6]

Core Insights - Ultragenyx Pharmaceutical Inc. has completed the rolling submission of its Biologics License Application (BLA) for DTX401, an AAV gene therapy aimed at treating Glycogen Storage Disease Type Ia (GSDIa) [1][2] - If approved, DTX401 will be the first therapy to address the underlying cause of GSDIa, which currently has no approved pharmacologic treatments [5] Company Overview - Ultragenyx is a biopharmaceutical company focused on developing novel therapies for serious rare and ultra-rare genetic diseases, with a portfolio aimed at addressing high unmet medical needs [6][7] - The company has received multiple designations from the FDA for DTX401, including Rare Pediatric Disease designation, orphan drug designation, Fast Track designation, and regenerative medicine advanced therapy (RMAT) designation [4] Clinical Development - The BLA submission for DTX401 is based on data from a clinical program involving 52 treated patients and up to six years of follow-up, demonstrating significant reductions in daily cornstarch intake and improved patient quality of life [2][3] - DTX401 has shown to improve G6Pase activity and reduce hepatic glycogen levels, which are critical for managing glucose metabolism in patients with GSDIa [4] Disease Context - GSDIa is a rare and life-threatening condition caused by mutations in the G6PC gene, leading to severe hypoglycemia and other complications [5] - The disease affects approximately 6,000 individuals in commercially accessible regions, highlighting the need for effective treatment options [5]

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ultragenyx Pharmaceutical, Inc. for possible securities fraud following the failure of its clinical trials, which has led to a significant drop in the company's stock price [1][3]. Group 1: Company Performance - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies for setrusumab (UX143) did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates [3]. - Although the studies showed improvements in secondary endpoints related to bone material density, these did not correlate with a statistically significant reduction in fractures [3]. - Following the announcement, Ultragenyx's stock price fell by $14.87 (43.49%) to open at $19.32 per share, marking a new 52-week low, significantly below the previous low of $25.81 [3]. Group 2: Legal Actions - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, and has a history of recovering over $5.5 billion for aggrieved investors [3]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims [2].

Core Insights - Shares of Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma (MREO) fell significantly by 42.3% and 87.6% respectively after disappointing results from phase III studies evaluating setrusumab for osteogenesis imperfecta treatment [1][2] Study Results - The Orbit and Cosmic studies did not achieve statistical significance for their primary endpoints related to annualized clinical fracture rate compared to placebo or bisphosphonates [2][7] - Both studies showed statistically significant improvements in bone mineral density (BMD) as a secondary endpoint, with no changes in safety profiles [2][9] - In the Orbit study, participants had meaningful BMD improvements, but these did not lead to a reduction in fracture rates [9] - The Cosmic study indicated that while BMD improvements were observed in a younger patient population, the reduction in fracture rates compared to bisphosphonates was not statistically significant [10] Company Actions - Ultragenyx is reviewing its operations and will implement significant cost-reduction measures following the study results [3][7] - The company is conducting additional analyses on the data from both studies to explore other bone health and clinical endpoints beyond fractures [10] Stock Performance - Over the past six months, Ultragenyx shares have declined by 45.7%, while Mereo BioPharma shares have dropped by 89.7%, contrasting with a 25.9% increase in the industry [4]